Therapeutic Advances in Musculoskeletal Disease

Papers
(The H4-Index of Therapeutic Advances in Musculoskeletal Disease is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Is there wastage in the research resources for ankylosing spondylitis? An analysis of clinical trial discontinuation and nonpublication outcome77
Actigraphy-derived physical activity levels and circadian rhythm parameters in patients with psoriatic arthritis: relationship with disease activity, mood, age and BMI42
An update on the use of conventional and biological disease-modifying anti-rheumatic drugs in hand osteoarthritis37
Anti-sclerostin antibodies: a new frontier in fragility fractures treatment35
Stakeholder perspectives on musculoskeletal pain assessment and management in the UK: a qualitative study31
The socioeconomic status of patients with ankylosing spondylitis and its association with the burden of the disease and permanent disability: a cross-sectional cluster analysis27
Drug retention of TNF versus IL-23 inhibitors in psoriatic arthritis: a multicenter real-life cohort study27
Similarities and differences: disentangling the intersection between axial psoriatic arthritis and axial spondyloarthritis26
Serious infection risk in older adults with RA receiving biologic or targeted synthetic DMARDs: the role of age at disease onset25
Counting the costs: a nationwide study on healthcare use following an adalimumab biosimilar switch in >1300 inflammatory arthritis patients25
Reduced bone mineral density in patients with idiopathic inflammatory myopathies: a case-control study19
Cardio-rheumatology: integrated care and the opportunities for personalized medicine19
The challenge of pharmacotherapy for musculoskeletal pain: an overview of unmet needs19
From advanced imaging to molecular insights: the state of the art in omics for axial spondyloarthritis17
Forced vital capacity as a survival predictor in systemic sclerosis-associated pulmonary hypertension16
0.1779260635376